Exciting Grant Collaboration for Rheumatoid Arthritis Research
Citryll, a pioneering clinical-stage biotech firm known for developing first-in-class therapeutics, has embarked on an exciting collaboration with leading rheumatology centers in the Netherlands to enhance treatments aimed at rheumatoid arthritis. This initiative has received substantial funding from ReumaNederland, the Dutch Arthritis Society, signaling a significant step forward in understanding and combating this complex disease.
Collaboration with Top Medical Institutions
The collaboration includes partnerships with renowned medical professionals and institutions, such as Prof. Dr. Sander Tas from the Amsterdam University Medical Centre (AUMC), Dr. Joannes Reijers from Leiden University Medical Centre (LUMC), Dr. Rogier Thurlings from Radboud University Medical Centre (RUMC), and Prof. Dr. Mike Nurmohamed from Reade. Together, they aim to delve deeper into the biology of Neutrophil Extracellular Trap (NET) formation and its relationship to the treatment outcomes of rheumatoid arthritis.
Understanding NETosis in Rheumatoid Arthritis
The project, aptly named Signs Of the Nature of NETosis in rheumatoid arthritis (SONNET), seeks to expand knowledge on how NETs play a crucial role in rheumatoid arthritis. NETosis is a specialized process of neutrophil cell death that results in the formation of NETs, which has been linked to disease progression and response to therapy. By exploring various subsets of samples, the team will correlate NET formation to RA disease status, and even assess the implications of NETs in related conditions such as cardiovascular disease.
Innovative Therapeutics for Patient Care
Renato Chirivi, Ph.D., Chief Technology Officer at Citryll, noted that despite available therapies, approximately 30% of rheumatoid arthritis patients do not achieve sustained remission. Addressing this critical gap, Citryll's leading candidate, CIT-013, represents a novel approach that targets NET formation and enhances the clearing of these inflammatory agents from tissues. Dr. Chirivi emphasized how crucial insights gathered from the SONNET project will propel the development of effective treatments for inflammatory diseases.
ReumaNederland's Commitment to Research
Jan-Willem Förch, CEO at ReumaNederland, expressed pride in supporting Citryll in this vital research partnership. He acknowledged the significant burden of rheumatoid arthritis on individuals' daily lives and emphasized that increasing understanding of NETosis is pivotal in their mission to improve patient outcomes. This collaboration is a significant stride toward enhancing the quality of life for many impacted by the condition.
Pioneering Approaches to Immune-Mediated Diseases
Citryll is at the forefront of developing a revolutionary approach to treating inflammatory diseases by specifically targeting Neutrophil Extracellular Traps. This strategy marks a breakthrough in therapeutic options that have historically underserved the patient population. By focusing on NET-related mechanisms, Citryll aims to create new therapeutic avenues that offer more effective solutions for individuals suffering from rheumatoid arthritis and other related inflammatory conditions.
CIT-013's Unique Mechanism of Action
The company's lead agent, CIT-013, distinguishes itself as a first-in-class monoclonal antibody characterized by a dual mechanism of action: it not only facilitates the clearance of existing NETs but also inhibits the production of new NETs. This comprehensive method has the potential to significantly improve treatment outcomes compared to conventional therapies, which often fall short in managing the complexities of immune-mediated inflammatory diseases.
Contact Information for Citryll
For further inquiries, you can reach out to Citryll's COO, Sjoerd van Gorp, via email at info@citryll.com. For media relations, contact ICR Consilium through citryll@icrinc.com.
Frequently Asked Questions
What is the purpose of Citryll's collaboration?
Citryll's collaboration aims to enhance understanding of Neutrophil Extracellular Trap (NET) biology and its relationship to rheumatoid arthritis treatments.
Who are the key partners in this research?
The research involves top rheumatology centers and specialists from institutions like AUMC, LUMC, and RUMC.
What is the significance of the SONNET project?
The SONNET project is designed to explore NET formation and its role in the pathology of rheumatoid arthritis, targeting personalized treatment options.
How does CIT-013 work?
CIT-013 enhances the clearance of existing NETs and inhibits the production of new NETs, offering a potentially more effective treatment strategy.
How can I contact Citryll for more information?
For inquiries, contact Sjoerd van Gorp at info@citryll.com or reach the media team at citryll@icrinc.com.
